Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study of entecavir ODT conversion in stable liver transplant patients
KCT0011293Phase 2Not yet recruiting
- Sponsor
- Chong Kun Dang
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of entecavir in hepatitis B (HBV) and decompensated cirrhosis, sponsored by Chong Kun Dang. Primary endpoints: Efficacy of entecavir ODT conversion and Safety of entecavir ODT conversion. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
entecavir
03
Conditions
hepatitis B (HBV)decompensated cirrhosis
Beyond the preview
Go deeper on KCT0011293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011293.